

Resource Summary Report

Generated by [dkNET](#) on Sep 2, 2026

HEL

RRID:CVCL_0001

Type: Cell Line

Proper Citation

RRID:CVCL_0001

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0001

Proper Citation: RRID:CVCL_0001

Description: Cell line HEL is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Erythroleukemia

Defining Citation: [PMID:2985879](#), [PMID:3159941](#), [PMID:3874327](#), [PMID:6177045](#), [PMID:7538619](#), [PMID:8558913](#), [PMID:9290701](#), [PMID:9510473](#), [PMID:9738977](#), [PMID:10739008](#), [PMID:11021758](#), [PMID:11226526](#), [PMID:14504097](#), [PMID:16408098](#), [PMID:16957166](#), [PMID:20164919](#), [PMID:22460905](#), [PMID:23955599](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27277069](#), [PMID:27397505](#), [PMID:29533902](#), [PMID:30285677](#), [PMID:30629668](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31160637](#), [PMID:31978347](#), [PMID:35839778](#), [PMID:36982453](#)

Comments: Donor information: Originally the patient was suffering from Hodgkin lymphoma., Population: Caucasian., Part of: LL-100 blood cancer cell line panel., Part of: Human Protein Atlas, Cell Atlas panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HEL

Synonyms: Hel, GM06141, GM06141B, Human ErythroLeukemia

Cross References: BTO:BTO_0000565, CLO:CLO_0003679, CLO:CLO_0023565, EFO:EFO_0006579, MCCL:MCC:0000187, CLDB:cl0, CLDB:cl1585, ArrayExpress:E-

MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, BioGRID_ORCS_Cell_line:210, BioSample:SAMN03471056, BioSample:SAMN03472269, BioSample:SAMN10987697, cancercellines:CVCL_0001, CCRID:3101HUMTCHu71, CCRID:4201HUM-CCTCC00071, CCTCC:GDC0071, Cell_Model_Passport:SIDM00594, ChEMBL-Cells:ChEMBL3308090, ChEMBL-Targets:ChEMBL613888, CLS:305022, Coriell:GM06141, Cosmic:787432, Cosmic:798663, Cosmic:850392, Cosmic:907053, Cosmic:919128, Cosmic:924040, Cosmic:947363, Cosmic:975251, Cosmic:976722, Cosmic:994176, Cosmic:996314, Cosmic:1012051, Cosmic:1013868, Cosmic:1037665, Cosmic:1070698, Cosmic:1078733, Cosmic:1122162, Cosmic:1127268, Cosmic:1139508, Cosmic:1139638, Cosmic:1140092, Cosmic:1151879, Cosmic:1168467, Cosmic:1170892, Cosmic:1171333, Cosmic:1176583, Cosmic:1191710, Cosmic:1192825, Cosmic:1601067, Cosmic:1604866, Cosmic:1633512, Cosmic:1943609, Cosmic:2089667, Cosmic:2131538, Cosmic:2306207, Cosmic:2649243, Cosmic-CLP:907053, DepMap:ACH-000004, DSMZ:ACC-11, DSMZCellDive:ACC-11, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, GDSC:907053, GEO:GSM482506, GEO:GSM743410, GEO:GSM887077, GEO:GSM888147, GEO:GSM1028243, GEO:GSM1446763, GEO:GSM1669874, GEO:GSM7701373, GEO:GSM7701374, IARC_TP53:21368, JCRB:JCRB0062, KCB:KCB 200808YJ, LiGeA:CCLE_453, LINCS_LDP:LCL-1053, PharmacDB:HEL_534_2019, PRIDE:PXD030304, Progenetix:CVCL_0001, PubChem_Cell_line:CVCL_0001, Ubigen:YC-C090, Wikidata:Q54882501

ID: CVCL_0001

Record Creation Time: 20220427T220330+0000

Record Last Update: 20260829T233651+0000

Ratings and Alerts

No rating or validation information has been found for HEL.

No alerts have been found for HEL.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 25 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Le T, et al. (2026) Cell shapes decode molecular phenotypes in image-based spatial proteomics. Cell systems, 17(6), 101589.

Lewis AC, et al. (2026) Inhibition of heme biosynthesis triggers cuproptosis in acute myeloid leukemia. *Cell*, 189(1), 215.

Saad J, et al. (2026) Predictors of response and rational combinations for the novel MCL-1 inhibitor MIK665 in acute myeloid leukemia. *Molecular oncology*, 20(2), 389.

Chung J, et al. (2026) Sialylated CD43 forms a glyco-immune barrier that restrains antileukemic immunity. *Science (New York, N.Y.)*, 392(6794), eady5196.

Pereira-Martins DA, et al. (2026) ?Np73 isoform defines a TP53-mutant-like poor-risk subgroup of acute myeloid leukemia. *Cell reports. Medicine*, 102540.

Hosogane M, et al. (2026) Variant-specific interaction of kinectin 1 with the multi-tRNA synthetase complex regulates ER sheet organization. *iScience*, 29(1), 114303.

Lin ME, et al. (2025) Inhibition of DOCK1 suppresses Notch signalling pathway and impairs leukaemogenesis. *British journal of haematology*, 207(1), 59.

Guillen Magaña JN, et al. (2025) Schlafen 12 Modulation and Targeting in Acute Myeloid Leukemia. *Cancer research communications*, 5(11), 2012.

Yanagiya R, et al. (2025) Aberrant expression of human endogenous retrovirus K9-derived elements is associated with better clinical outcome of acute myelocytic leukemia. *Retrovirology*, 22(1), 4.

Lin AY, et al. (2025) Targeting scavenger receptor class B type 1 with a bioinspired ligand induces apoptosis or ferroptosis in AML. *Blood neoplasia*, 2(4), 100122.

Caulier B, et al. (2024) CD37 is a safe chimeric antigen receptor target to treat acute myeloid leukemia. *Cell reports. Medicine*, 5(6), 101572.

Pritchard JE, et al. (2024) Non-canonical Hedgehog signaling mediates profibrotic hematopoiesis-stroma crosstalk in myeloproliferative neoplasms. *Cell reports*, 43(1), 113608.

Chang YH, et al. (2024) SETDB1 suppresses NK cell-mediated immunosurveillance in acute myeloid leukemia with granulo-monocytic differentiation. *Cell reports*, 43(8), 114536.

Fredon M, et al. (2024) Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells. *Cancer immunology research*, 12(8), 1090.

Chen EC, et al. (2023) Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 29(5), 878.

Hamza E, et al. (2023) Indoxyl sulfate impairs erythropoiesis at BFU-E stage in chronic kidney disease. *Cellular signalling*, 104, 110583.

Popescu B, et al. (2023) Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in FLT3- and KIT-mutant AML. *Cell reports. Medicine*, 4(11), 101290.

Gurska LM, et al. (2023) Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 29(5), 943.

Letson CT, et al. (2023) Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 29(15), 2919.

Blöchl C, et al. (2023) Transcriptionally imprinted glycomic signatures of acute myeloid leukemia. *Cell & bioscience*, 13(1), 31.